| HS Code | 247857 |
| Product Name | Aminopeptidase |
| Enzyme Type | Protease (exopeptidase) |
| Ec Number | EC 3.4.11.- |
| Source | Microbial (e.g., Aspergillus oryzae), animal tissues, and plants |
| Molecular Weight | Typically 30–100 kDa depending on isoform |
| Optimum Ph | 6.0–8.0 (varies by source) |
| Optimum Temperature | 37–50°C (varies by source) |
| Substrate Specificity | Hydrolyzes N-terminal amino acid residues from peptides and proteins |
| Inhibitors | Metal chelators (e.g., EDTA), bestatin, and heavy metal ions |
| Activators | Divalent metal ions such as Zn²⁺, Mn²⁺, and Co²⁺ |
| Applications | Food processing, protein hydrolysis, peptide synthesis, and analytical biochemistry |
As an accredited Aminopeptidase factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied as lyophilized powder in an airtight amber glass vial containing 1 gram, with desiccant, for laboratory use. |
| Container Loading (20′ FCL) | 20′ FCL shipment of Aminopeptidase: temperature-controlled, sealed container to maintain enzyme stability and prevent contamination. |
| Shipping | Aminopeptidase is shipped as a temperature-sensitive enzyme solution or lyophilized powder. Transport requires cold-chain conditions, typically on dry ice or refrigerated gel packs, to preserve enzymatic activity. Ensure leak-proof, clearly labeled packaging with hazard documentation, and avoid freeze-thaw cycles during transit to maintain product stability and performance. |
| Storage | Store aminopeptidase lyophilized powder at -20°C, protected from moisture and light. For solutions, aliquot and store at -20°C or -80°C for long-term stability; short-term storage at 2–8°C is acceptable. Avoid repeated freeze-thaw cycles, as they reduce enzymatic activity. Always follow the manufacturer’s guidelines. |
| Shelf Life | Store lyophilized aminopeptidase at -20°C; stable for up to 12 months. Avoid repeated freeze-thaw cycles. |
In the production of whey protein hydrolysates for sports nutrition and enteral formulations, aminopeptidase from Aspergillus oryzae is applied as a secondary exopeptidase after a controlled endoprotease prehydrolysis step, because its sequential release of N-terminal hydrophobic residues—leucine, isoleucine, valine, phenylalanine—reduces the bitter peptide fraction that survives endoprotease cleavage. The hydrolytic process is operated on WPC80 or WPI reconstituted to 8–12% crude protein, adjusted to pH 6.8–7.2 with 1 M KOH or K₂HPO₄, and heated to 50–55 °C in a jacketed batch reactor with low-shear agitation at 60–120 rpm. A commercial aminopeptidase preparation standardized to 500–1,000 LAPU/g is dosed at 0.05–0.30% w/w relative to total crude protein, following a dose-response trial using the pH-stat method with 0.1 M NaOH titration at pH 7.0 to maintain the target degree of hydrolysis, typically DH 4–8% before aminopeptidase addition and final DH 8–14% after 2–6 h. Inactivation is carried out at 90 °C for 10 min or 85 °C for 20 min, depending on protein concentration and fouling tendency of the plate heat exchanger; the inactivation step is verified by measurement of residual enzyme activity below 0.05% of the initial dose using a leucine aminopeptidase assay calibrated against the FCC 12 enzyme preparation monograph. The hydrolysate is then clarified by centrifugation, ultrafiltered through a 10 kDa polyethersulfone membrane at 45–50 °C and 3–4 bar transmembrane pressure, evaporated to 35–45% dry matter, and spray-dried with inlet air 180–190 °C and outlet air 80–85 °C. The terminal product is a low-bitter whey protein hydrolysate powder with free amino nitrogen of 4.0–7.0 g/100 g product, used in ready-to-mix sports nutrition powders, clear hydrolyzed whey beverages, and enteral nutrition formulas. Compliance in the European Union falls under Regulation (EC) No 1332/2008 on food enzymes, Article 4, and the resulting food for special medical purposes must comply with Commission Delegated Regulation (EU) 2016/128; in the United States, the enzyme preparation must meet FCC 12 limits for heavy metals (<10 mg/kg as Pb) and microbial specification, and conventional foods or dietary supplements are subject to 21 CFR Part 184 enzyme preparation provisions where applicable.
On production-scale lines, the main bottleneck is not enzyme kinetics but membrane flux decline caused by residual aggregated peptides; 10 kDa PES ultrafiltration membranes show flux drops from 45–55 L/m²·h to 20–30 L/m²·h after 6 h when the feed exceeds 12% dry matter, requiring diafiltration at 2–3 volumes to maintain final free amino nitrogen in powder. Batch-to-batch variance in whey protein substrate—especially glycomacropeptide content, fat content above 1.5%, and preheat treatment—changes aminopeptidase dose by up to 0.1% w/w protein, so incoming substrate is standardized through β-lactoglobulin/α-lactalbumin ratio by HPLC. The powder must meet osmolarity limits of 400–600 mOsm/L in ready-to-feed enteral products, which is directly governed by free amino acid profile. This operational boundary explains why the aminopeptidase activity unit rather than crude protein weight is used for final dose confirmation.
Processors evaluating aminopeptidase for neutral-pH dairy protein beverages must reconcile the enzyme’s pH optimum with the low bitterness threshold required in UHT-sterilized products. In a typical trial, skimmed milk protein isolate or micellar casein concentrate is reconstituted to 6–8% protein, adjusted to pH 6.7–7.0 with trisodium citrate or dipotassium phosphate, and preheated to 50–55 °C before enzyme addition at 0.01–0.05% w/w of substrate protein, using a preparation standardized to 500–1,000 LAPU/g. The reaction is run for 60–180 min under continuous circulation in a plate-and-frame heat exchanger, during which free amino nitrogen rises from a baseline of 0.2–0.4 g/L to 0.8–1.5 g/L, determined by the ninhydrin method with L-leucine calibration. The enzyme is inactivated at 95 °C for 5 min prior to downstream blending with lactose, fat, stabilizers and minerals; insufficient inactivation results in continued hydrolysis during storage, producing a shelf-life-dependent increase in Maillard reactivity and viscosity instability. The treated protein base is then homogenized in two-stage homogenization at 200/50 bar, UHT-sterilized at 140 °C for 3–5 s, and aseptically filled. Terminal product types include neutral-pH ready-to-drink dairy protein shakes, breakfast meal replacement beverages, and high-protein lactose-reduced dairy drinks. Compliance for the enzyme component follows Regulation (EC) No 1332/2008 Article 4 in the EU; in the United States, the finished beverage is subject to FDA pasteurized milk ordinance requirements for Grade A dairy processing and the enzyme preparation must satisfy FCC 12 activity and purity specifications. A documented limitation is the enzyme’s reduced activity below pH 6.0, which precludes direct application in acidic clear whey beverages without a separate neutral-phase prehydrolysis step.
In accelerated Cheddar and enzyme-modified cheese manufacture, aminopeptidase is introduced at the curd-salting stage rather than into the cheese milk, because direct addition to milk increases peptide hydrolysis too early and alters rennet coagulation kinetics. The enzyme preparation, typically 500–1,000 LAPU/g, is dispersed in pasteurized water and applied at 0.02–0.08% w/w relative to curd protein after whey drainage and before pressing; the target is to increase free amino nitrogen in 90-day Cheddar from a control of 0.6–0.9 g/100 g dry matter to 1.2–1.8 g/100 g dry matter, without causing excessive paste spread or bitterness. Pressing is conducted at 0.3–0.5 MPa for 12–16 h, followed by vacuum packaging and ripening at 10–12 °C for 3–6 months. For enzyme-modified cheese pastes, a 10–14 day accelerated process is used at 25–35 °C with 0.2–0.5% w/w enzyme relative to curd dry matter, and the final paste is heat-inactivated at 85–90 °C for 20 min before milling and blending with dairy ingredients. Terminal product types include reduced-fat Cheddar with restored flavour intensity, processed cheese ingredient bases, and enzyme-modified cheese pastes for sauces, snacks and prepared meals. The applicable standards for the enzyme component are Regulation (EC) No 1332/2008 in the EU and the FCC 12 enzyme preparation monograph in the United States; cheese composition and labelling must comply with Regulation (EU) No 1308/2013 or 21 CFR 133.113 for Cheddar. Operational boundaries include the need to avoid aminopeptidase contact with high-salt brine above 18% NaCl, which sharply reduces exopeptidase turnover in EMC production.In EMC production, batch reactors of 500–2,000 L are operated under vacuum at 25–35 °C for 10–14 days with continuous mixing at 30–60 rpm; the aminopeptidase-to-endoprotease ratio becomes the critical variable because excess exopeptidase drives free amino nitrogen above 2.5% of dry matter and can produce a broth-like aroma rather than cheese-type background. The final EMC paste is standardized to 15–20% moisture, 25–35% fat, and pH 5.2–5.6 before drum drying or spray cooling; packaged enzyme-modified cheese must meet sodium and phosphate label constraints under Regulation (EU) No 1169/2011 and 21 CFR 133 for pasteurized process cheese ingredients where applicable. Published data for aminopeptidase-specific EMC formulations is limited; process validation therefore uses a central composite design varying enzyme dose, temperature and time, with gas chromatography–mass spectrometry monitoring of branched-chain volatile acids such as isovaleric acid.
Laminated cracker and hard biscuit lines operate within a narrow aminopeptidase dose window because the enzyme liberates Maillard-active amino acids from wheat gluten while leaving dough viscoelasticity sufficiently intact. The enzyme preparation, standardized to 500–1,000 LAPU/g, is added at 0.002–0.008% w/w of flour, typically into the sponge stage with water at 28–32 °C; the sponge is fermented for 2–4 h at pH 5.5–6.0 before final dough mixing, laminating and cutting. Process control relies on monitoring dough extensibility with an extensograph at 45 min and 135 min, because excessive hydrolysis of gluten peptides reduces sheet integrity and increases cracker breakage; the addition range is therefore capped at 0.008% w/w of flour, above which the elastic modulus of the mature sponge declines measurably. Baking is performed in a direct gas-fired tunnel oven at 220–260 °C for 5–8 min, and top-surface browning is evaluated by reflectance spectrophotometry using CIE L* values, with a target L* reduction of 6–12 units relative to the control. Terminal product types include fermented crackers, hard sweet biscuits and enzyme-assisted low-sugar baked snacks. Compliance follows Regulation (EC) No 1332/2008 in the European Union and FCC 12 in the United States; flour and dough testing methods include AACCI Method 54-21.02 for farinograph and AACCI Method 10-10.03 for baking quality where applicable. The boundary condition is the flour’s endogenous protease activity: high levels of pre-existing protease from insect-damaged or sprouted wheat shift the aminopeptidase dose toward the lower end to avoid sticky dough and open grain.
The high-salt liquid-state moromi fermentation of soybean and wheat uses aminopeptidase supplementation to increase free amino nitrogen and glutamate concentrations before heat treatment and bottling. In a conventional koji-based process, steamed defatted soybean and roasted wheat are inoculated with Aspergillus sojae or Aspergillus oryzae and incubated at 28–35 °C for 40–48 h to form koji; the koji is then mixed with 18–20% NaCl brine to produce moromi. Aminopeptidase is added during moromi mixing or after 30 days of fermentation at 0.01–0.05% w/w of raw protein, using a salt-tolerant liquid preparation standardized to 500–1,000 LAPU/g. The moromi is held at 28–32 °C for 60–120 days with periodic aeration; release of free glutamic acid, aspartic acid and alanine is measured by HPLC after post-column ninhydrin derivatization, with a target amino nitrogen concentration of 0.8–1.2 g/100 mL in finished soy sauce, as defined by the amino nitrogen method in GB/T 18186-2000 or equivalent internal AOAC verification. After fermentation, raw soy sauce is pressed through nylon mesh filter cloth, pasteurized at 85 °C for 30 min, clarified and blended. Terminal product types include naturally brewed soy sauce, reduced-salt soy sauce, and hydrolyzed vegetable protein seasonings where the same enzyme preparation is used in acid-assisted or enzymatic HVP after neutralization. Compliance for the enzyme component in the EU follows Regulation (EC) No 1332/2008; in the United States the enzyme must satisfy FCC 12 specifications; the finished soy sauce must comply with CODEX STAN 302-2011 where export documentation requires. The operational limitation is the enzyme’s loss of activity above 18% NaCl over extended ageing, which requires addition after partial salt equilibration rather than at the start of moromi mixing.
For companion animal palatability systems, liquid and spray-dried animal protein hydrolysates are produced from poultry viscera, liver, or porcine mucosal tissue using a two-stage hydrolysis protocol in which an endoprotease first cleaves high-molecular-weight protein, followed by aminopeptidase to raise free amino nitrogen and enhance volatile aroma precursors. Raw material is minced to 3–5 mm, mixed with water to 60–70% moisture, adjusted to pH 6.5–7.5 with sodium hydroxide or phosphoric acid, and heated to 50–55 °C. Endoprotease is dosed at 0.1–0.3% w/w of raw protein for 2–4 h; aminopeptidase is then added at 0.05–0.20% w/w of raw protein and hydrolysis is continued for another 2–6 h until free amino nitrogen reaches 2.5–4.5% of total nitrogen. The digest is heated to 95 °C for 15 min for enzyme inactivation and pathogen reduction in accordance with the thermal kill step expected under Regulation (EC) No 1069/2009 for Category 3 animal by-products, then decanted, centrifuged to remove bone and acid-insoluble fractions, evaporated to 40–50 °Bx, and spray-dried or used directly as a liquid palatant. Terminal product types include dry dog and cat kibble coatings, retorted wet pet food gravy enhancers, and liquid palatant systems for companion animal diets. In the United States, the ingredient is regulated under 21 CFR 570/571 as a food additive or GRAS ingredient for animal feed, and labelling must align with AAFCO ingredient definitions; the enzyme preparation must meet FCC 12 purity limits for heavy metals and microbial counts. The limiting condition is high lipid content: raw materials exceeding 12–15% ether extract require pre-emulsification or centrifugal fat removal, because a fat film on protein particles reduces aqueous enzyme contact and increases batch-to-batch free amino nitrogen variability.Competitive Aminopeptidase prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The product designated AP-LAP-100L is a soluble leucine aminopeptidase preparation obtained from porcine kidney and classified under EC 3.4.11.1. It is supplied as an ammonium sulfate suspension at 2.9 M (NH₄)₂SO₄, pH 7.2, with a typical release activity of 15–25 U/mg protein when assayed against L-leucine-p-nitroanilide at 25 °C and pH 7.2. One unit of enzyme activity is defined as the hydrolysis of 1.0 µmol of L-leucine-p-nitroanilide per minute under the stated conditions. The native enzyme is a homohexamer with a subunit molecular mass near 51 kDa and a native mass of approximately 300 kDa. Activity is dependent on Zn²⁺ at the active site, and the cation requirement is enhanced by Mn²⁺ or Mg²⁺ at 1–5 mM. The preparation is standardized by activity per volume rather than per protein mass to reduce dosing error from residual ammonium sulfate; protein content variance in the suspension is typically 10–15% across production batches. Shipment and storage are maintained at 2–8 °C, and freeze-thaw cycles are to be avoided because they produce insoluble aggregates and reduce soluble activity by a measurable amount. The product is used for terminal amino acid release, peptide ladder sequencing support, debittering of protein hydrolysates after endoprotease treatment, and selective N-terminal truncation in laboratory and pilot-scale reactors.
Exposure of AP-LAP-100L to process buffers below pH 5.0 induces dissociation of the hexameric assembly and loss of the catalytic Zn²⁺ coordination sphere. The pH-stability envelope for porcine kidney leucine aminopeptidase places the lower operational boundary near pH 6.5; activity is highest near pH 8.5–9.0 for L-leucyl substrates, but process stability is often better maintained at pH 7.0–8.0 in long-duration hydrolysis. Heat exposure follows a similar threshold: pre-incubation at 60 °C for 15 min produces measurable loss, while routine hydrolysis at 37–45 °C balances catalytic rate and deactivation. For production reactors, temperature control should maintain the jacket setpoint within ±0.5 °C; excursions above 50 °C in a 100 L stirred vessel can decrease batch activity by 5–15% over 2 h. The preparation is incompatible with direct addition of ethylenediaminetetraacetic acid or 1,10-phenanthroline at chelating concentrations above 1 mM because metal removal is only partially reversible after buffer exchange. If chelators are unavoidable in downstream formulation, supplemental ZnCl₂ or MnCl₂ must be restored and verified by activity assay. Published data for this specific product configuration across all pH and temperature combinations is limited; therefore, a matrix-specific stability run of at least 3 points bracketing the intended operating pH is required before scale-up.
Because the S1 pocket of leucine aminopeptidase accommodates hydrophobic and basic N-terminal residues, AP-LAP-100L is applied where selective removal of N-terminal Leu, Met, Arg, or Phe from peptides or partially hydrolyzed proteins is required. This action is distinct from carboxypeptidase A, which releases C-terminal aromatic or aliphatic residues, and from endoproteases, which cleave internal bonds and generate new N-termini. In protein hydrolysate debittering, aminopeptidase treatment follows an initial endoprotease step because N-terminal hydrophobic amino acids contribute to bitter taste, and their removal shortens the perceived bitter peptide length. A pilot-scale screening range is 0.1–1.0 U enzyme per gram protein in a 50 L jacketed stirred-tank reactor with pH-stat control at pH 7.5 and 45 °C for 2–4 h. The exact dose is established against sensory bitterness scores and free amino nitrogen accumulation; published data for this specific product in whey or casein matrices is limited. When the substrate is a high-solids stream above 20% dry matter, water activity reduction and metal-ion partitioning require re-optimization of the activator concentration because activity per unit volume can diverge from dilute assay conditions.
High-solids hydrolysis streams above 20% dry matter reduce available water activity and alter free metal-ion partitioning. AP-LAP-100L activity is sensitive to free Zn²⁺ and Mn²⁺; addition of 1–5 mM MnCl₂ or MgCl₂ is recommended when chelating peptides, phytate, or phosphate-based buffer salts are present. Calibration is performed against L-leucine-p-nitroanilide hydrolysis at 405 nm, 25 °C, pH 7.2, with one unit defined as formation of 1.0 µmol p-nitroaniline per minute. In turbid food hydrolysates, centrifugation at 10,000×g for 10 min before spectrophotometric reading is required to avoid particulate interference; filtration through 0.45 µm membrane may be substituted if the hydrolysate has been pre-clarified. The product is not compatible with prolonged exposure to air-liquid interfaces generated by high-shear mixers; impeller tip speeds above 3 m/s in unbaffled vessels increase foam formation and may accelerate interfacial denaturation. When foam is observed, antifoam agents should be qualified for enzyme compatibility because silicone-based antifoams can stabilize the interface but may reduce filtrate flux in downstream 10 kDa membrane operations. Batch-to-batch activity variance is controlled by normalizing the dosing rate to the certificate-of-analysis value rather than adding a fixed volume; failure to normalize produces free amino nitrogen variability of ±8–12% in high-throughput lines.
| Parameter | Specification | Reference Method |
|---|---|---|
| Appearance | Off-white ammonium sulfate suspension | Visual inspection |
| Activity | 15–25 U/mg protein | L-leucine-p-nitroanilide hydrolysis, 405 nm, 25 °C, pH 7.2 |
| pH | 7.0–7.5 | Direct pH measurement at 25 °C |
| Storage | 2–8 °C; do not freeze | Retain activity after 12 months under sealed storage |
| Total aerobic microbial count | <10³ CFU/g | ISO 4833-1:2013 |
| Lead | <5 mg/kg | FCC enzyme monograph acid digestion and atomic absorption |
For activity release, a two-point calibration using L-leucine-p-nitroanilide concentrations of 0.5 mM and 2.0 mM is sufficient to verify linearity; absorbance readings above 2.0 AU should be diluted and reassayed because product inhibition by p-nitroaniline can occur above 1 mM p-nitroaniline in some buffer systems. The assay is sensitive to free Zn²⁺ carryover; therefore, dialysis cassettes or desalting columns with a 10 kDa molecular-weight cut-off should be used when transferring the enzyme into custom buffers. If turbidity persists after centrifugation, use a blank containing substrate and buffer without enzyme, and subtract the blank at each timepoint. Published data for the exact p-nitroaniline inhibition threshold in food hydrolysate matrices is limited, but the laboratory method is robust when absorbance is kept below 2.0 AU.
The steady-state kinetic profile of AP-LAP-100L with L-leucine-p-nitroanilide shows Michaelis-Menten behavior only when free metal-ion content is controlled. Reported Km values for porcine kidney leucine aminopeptidase with this substrate range from 0.1 mM to 1.0 mM depending on buffer identity and Mn²⁺ concentration; published data for the exact product lot is limited. For process hydrolysis, substrate concentrations are typically far above Km, but peptide substrates containing proline at the P1′ position are cleaved slowly or not at all. This explains the need to combine AP-LAP-100L with proline-specific exopeptidases when hydrolyzing casein or wheat gluten fractions with high proline density. Competitive inhibition by bestatin is observed at 10 µM, and this compound is therefore used as a diagnostic inhibitor in quality control to confirm aminopeptidase identity. Amastatin and puromycin may also inhibit activity at micromolar concentrations, and these agents must not be present as residues in food-contact cleaning solutions.
On a continuous hydrolysis line, the suspension is metered into a jacketed plug-flow or continuous stirred-tank reactor using a peristaltic pump fitted with low-shear tubing. Retention time distribution in a CSTR can leave 5–10% of the feed under-reacted when the mean residence time is 2 h; a two-stage cascade reduces this tail. Diafiltration of the finished hydrolysate through a 10 kDa polyethersulfone membrane removes residual ammonium sulfate and stops continued enzyme action. Batch-to-batch variance in activity is controlled by adjusting the dosing rate to the certificate-of-analysis value rather than adding a fixed volume; failure to normalize the dose produces free amino nitrogen variability of ±8–12% in high-throughput lines. Published data for this specific product configuration in continuous high-solids hydrolysis is limited, so qualification runs with 3 consecutive batches are required to establish process capability. The product is porcine-derived; therefore, segregated storage, cleaned transfer lines, and label review are required for kosher, halal, and vegan product streams. Avoid combining with amine-based buffer additives at concentrations above 50 mM because the resulting alkaline pH shift above pH 9.5 accelerates autolytic degradation and shortens batch stability.
In a 50 L reactor equipped with a bottom-sweep agitator, shear sensitivity is less pronounced than air entrainment. A low-shear axial-flow impeller operating at 50–100 rpm is sufficient for suspension homogeneity; radial-flow Rushton impellers at 300 rpm can create a vortex that pulls headspace oxygen into the liquid and increases foam-associated activity loss. If high-shear dispersion is required upstream for substrate homogenization, enzyme dosing should occur after cooling to 45 °C and after foam collapse. Published data for shear-induced inactivation of soluble aminopeptidase is limited; therefore, maximum impeller tip speed is set at 3 m/s as a process boundary rather than an absolute inactivation threshold. Defoaming loops that recirculate foam into the liquid return line should be avoided, because repeated passage through the pump head can cause mechanical denaturation.
Replacement of an endoprotease cocktail with AP-LAP-100L alone changes the mass-balance profile of whey protein hydrolysates because terminal hydrolysis does not generate the same internal peptide size distribution. In a 100 L pilot run at 10% whey protein isolate, dosing AP-LAP-100L at 0.5 U/g protein for 3 h at 45 °C and pH 7.5 typically reduces bitterness sensorially but may leave longer internal peptide sequences intact. This outcome is functionally different from an endoprotease that reduces average molecular weight but can expose new N-terminal hydrophobic residues. Filtration through a 10 kDa spiral-wound membrane after aminopeptidase treatment shows lower fouling resistance when compared with endoprotease-only hydrolysis in the same system, but the hydrolysate may require a subsequent endoprotease step if the target is extensive chain-length reduction below 5 kDa. The use of aminopeptidase as the sole enzyme is not recommended for complete hydrolysates intended for hypoallergenic infant formula; published data for this specific product in that application is limited. When bitterness reduction is measured, the evaluation should use a trained panel calibrated against caffeine reference solutions at 0.05–1.0 g/L; if no sensory panel is available, free amino nitrogen analysis by o-phthaldialdehyde derivatization at 340 nm can track the extent of hydrolysis but cannot directly quantify bitterness perception.
| Enzyme class | EC code | Cleavage site | Metal/cofactor requirement | Typical pH range |
|---|---|---|---|---|
| Aminopeptidase AP-LAP-100L | EC 3.4.11.1 | N-terminal amino acid | Zn²⁺; enhanced by Mn²⁺/Mg²⁺ at 1–5 mM | 7.0–9.0 |
| Carboxypeptidase A | EC 3.4.17.1 | C-terminal aromatic or aliphatic | Zn²⁺ | 7.5–8.5 |
| Proline iminopeptidase | EC 3.4.11.5 | N-terminal proline | None or Mn²⁺ | 6.0–8.0 |
| Subtilisin endoprotease | EC 3.4.21.62 | Internal peptide bonds | Ca²⁺-stabilized | 7.0–11.0 |
For food-processing applications, AP-LAP-100L is released to the Food Chemicals Codex monograph for enzyme preparations, with total heavy metals below 10 mg/kg and lead below 5 mg/kg. The product is not suitable for use in parenteral or injectable applications unless further purification, endotoxin reduction, and viral validation are performed. Bench-scale trials should be conducted with the same water hardness and chelator load as the production water; otherwise metal-ion availability can shift activity by more than 20% between laboratory and plant scales. Shipment is maintained with cold-chain packaging, and the preparation should be re-qualified after 72 h of uncontrolled temperature exposure above 25 °C. Site-specific validation under local food safety programs remains mandatory.
